AstraZeneca & MSD v. Sandoz: Olaparib Patent Infringement Action Consolidated
AstraZeneca AB, MSD International Business GmbH, Kudos Pharmaceuticals, and AstraZeneca UK filed suit against Sandoz in the District of New Jersey asserting two patents covering LYNPARZA® (olaparib) tablets. The case was consolidated with two related actions within just 24 days of filing, folding it into a broader multi-case olaparib patent dispute.
Multi-plaintiff olaparib patent dispute funnelled into consolidated NJ docket
On May 7, 2024, AstraZeneca AB — alongside MSD International Business GmbH, Kudos Pharmaceuticals Limited, and AstraZeneca UK Limited — filed a patent infringement action against Sandoz, Inc. in the United States District Court for the District of New Jersey. The complaint asserted two patents, US11970530B2 and US11975001B2, both relating to olaparib, the active ingredient in LYNPARZA®, a PARP inhibitor approved for treatment of certain BRCA-mutated cancers. The filing is consistent with Hatch-Waxman litigation patterns, where branded pharmaceutical holders challenge generic applicants upon notification of an ANDA submission.
The case was closed on May 31, 2024 — just 24 days after filing — not on the merits, but through consolidation. By stipulated court order, case no. 3:24-cv-05889 was merged with two earlier-filed related actions: nos. 3:23-796 and 3:24-641. This consolidation mechanism is standard practice in multi-ANDA pharmaceutical patent disputes, allowing a single judge to manage overlapping discovery, claim construction, and trial schedules across related proceedings. The substantive infringement and validity issues remain live and unresolved within the consolidated docket.
The 24-day timeline to consolidation suggests the parties and the court moved quickly to align this new filing with pre-existing parallel proceedings, likely reflecting that olaparib patent litigation against Sandoz was already at an advanced stage in the earlier cases. The public record for this individual docket number does not reveal terms, damages figures, or merits rulings. Practitioners monitoring the olaparib patent landscape should track the consolidated proceedings under the earlier case numbers for substantive developments.
Filing to Case Consolidated in 24 days
24 days to consolidation — well below the typical district court lifecycle, reflecting coordinated case management
Case consolidated: what the court order means for both parties
Consolidation merges related olaparib cases into one docket
Court consolidation under Fed. R. Civ. P. 42(a) combines actions sharing common questions of law or fact. Here, cases 3:23-796, 3:24-641, and 3:24-cv-05889 were merged by stipulated order. The infringement claims, patent validity defences, and any ANDA-related issues will be litigated jointly. No substantive ruling was made; the action continues under the lead docket number.
Procedural — no merits rulingPlaintiffs preserve all claims in a coordinated forum
Consolidation is broadly neutral-to-favourable for plaintiffs managing multi-patent, multi-ANDA campaigns. AstraZeneca and its co-plaintiffs retain all asserted claims on US11970530B2 and US11975001B2. Coordinated proceedings typically reduce duplicative discovery burdens and allow plaintiffs to present a unified claim construction position across overlapping patent families covering LYNPARZA®.
Claims preservedSandoz faces coordinated litigation across multiple olaparib patents
For Sandoz, consolidation means a single coordinated proceeding that encompasses multiple asserted patents and potentially multiple ANDA filings. While this can streamline case management, it concentrates infringement and validity disputes in one forum. Sandoz’s invalidity and non-infringement defences will be adjudicated against a broader set of patents simultaneously, which can increase litigation complexity and cost.
Broader exposure in one docketOlaparib market entry timeline remains uncertain for generic competition
LYNPARZA® is a high-value oncology product. Consolidated Hatch-Waxman litigation typically triggers a 30-month stay of FDA approval for the ANDA, meaning generic market entry by Sandoz is delayed while the merged cases proceed. The outcome of the consolidated docket on US11970530B2 and US11975001B2 will be a key determinant of when olaparib generics can reach the US market.
Generic entry delayed pending trialFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AstraZeneca AB | Individual | Global pharmaceutical group — holder of US11970530B2 and US11975001B2 covering LYNPARZA® olaparibSearch in Eureka ↗ |
| Co-Plaintiff | MSD International Business, GmbH | Company | Search in Eureka ↗ |
| Co-Plaintiff | Kudos Pharmaceuticals Limited | Individual | Search in Eureka ↗ |
| Co-Plaintiff | AstraZeneca AB | Individual | Search in Eureka ↗ |
| Co-Plaintiff | AstraZeneca UK Limited | Individual | Search in Eureka ↗ |
| Defendant | Sandoz, Inc. | Company | Sandoz, Inc. — generic pharmaceutical company and ANDA applicant for olaparib tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for AstraZeneca ABSearch in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing AstraZeneca ABSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order — entered by stipulation of the parties — carries no merits determination on infringement or validity of US11970530B2 or US11975001B2. The language ‘hereby consolidated’ is purely procedural, transferring management of this docket into coordinated proceedings with cases 3:23-796 and 3:24-641. Both parties retain their full legal positions; substantive rulings on LYNPARZA® patent rights will emerge only from the lead consolidated docket going forward.
US11970530B2 & US11975001B2 — LYNPARZA® olaparib PARP inhibitor formulations
US11970530B2 (application no. US17/399527) and US11975001B2 (application no. US18/312333) are recent-grant US patents covering olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor used in LYNPARZA® tablets at 100 mg and 150 mg doses. PARP inhibitors exploit synthetic lethality in BRCA-mutated tumour cells, representing a mechanistically distinct class of targeted oncology therapy. The relatively recent application numbers suggest these may be continuation or divisional filings within a broader olaparib patent family, extending protection over specific formulation, composition, or method-of-use aspects of the commercial product.
For the oncology pharmaceutical sector, these patents represent a critical layer of lifecycle protection for one of AstraZeneca’s flagship cancer medicines. LYNPARZA® has received approvals across multiple BRCA-associated cancer indications including ovarian, breast, pancreatic, and prostate cancers, making its patent estate commercially significant. Any generic entrant — including Sandoz — must either design around these formulation patents, successfully invalidate them, or wait for expiry. The co-ownership and licensing structure involving Kudos Pharmaceuticals and MSD adds complexity that may influence validity and standing arguments in the consolidated proceedings.
Should you run an FTO analysis against US11970530B2 and US11975001B2?
Any pharmaceutical company developing a generic or follow-on olaparib tablet product — at 100 mg or 150 mg dosage strengths — should treat these two patents as high-priority FTO targets. As recently granted US patents actively asserted in Hatch-Waxman litigation, they reflect AstraZeneca’s current enforcement posture. R&D and regulatory teams planning ANDA submissions or 505(b)(2) applications for PARP inhibitor products must assess both claim scope and the validity landscape before committing to development timelines.
PatSnap Eureka’s FTO Search Agent can map the full olaparib patent family — including pending continuations and divisionals — against your product candidate’s formulation parameters. Eureka surfaces prior art relevant to validity challenges and identifies claim language that may create design-around opportunities, helping your team make evidence-based go/no-go decisions before costly clinical or regulatory investment.
Run a freedom-to-operate analysis on US11970530B2 to assess your product’s exposure
Run FTO in Eureka →Similar PARP inhibitor Hatch-Waxman patent cases in NJ District Court
Explore related Hatch-Waxman infringement cases involving PARP inhibitor and oncology pharmaceutical patents litigated in the District of New Jersey.
What this case signals for the PARP inhibitor pharmaceutical IP landscape
Consolidated Hatch-Waxman filings over LYNPARZA® patents signal an aggressive, coordinated defence of AstraZeneca’s olaparib franchise against generic entry.
Multi-case consolidation is a hallmark of high-stakes ANDA pharmaceutical battles
When plaintiffs file successive actions as new ANDA notifications arrive, courts routinely consolidate them. This pattern with LYNPARZA® suggests multiple generic applicants or multiple patent families are in play. IP teams monitoring olaparib should track all three consolidated dockets for claim construction rulings that will bind all parties.
Two newly-issued patents being enforced signals a continuing patent prosecution strategy
US11970530B2 and US11975001B2 are recent grants. Their assertion in active Hatch-Waxman litigation suggests AstraZeneca is prosecuting continuation or divisional applications to extend patent coverage over LYNPARZA® formulations, a common lifecycle management tactic in oncology. Competitors should audit the olaparib patent family for additional pending applications.
AB v Sandoz — key questions answered
Case 3:24-cv-05889 was a patent infringement action filed by AstraZeneca, MSD, Kudos Pharmaceuticals, and AstraZeneca UK against Sandoz asserting US11970530B2 and US11975001B2 over LYNPARZA® olaparib tablets. The case was closed after 24 days by stipulated order consolidating it with related cases 3:23-796 and 3:24-641. No merits ruling was issued; substantive proceedings continue in the consolidated docket.
The patents asserted in case 3:24-cv-05889 are US11970530B2 (application US17/399527) and US11975001B2 (application US18/312333), both covering olaparib — the active ingredient in LYNPARZA® tablets at 100 mg and 150 mg strengths. These are recently granted US patents that appear to be part of a broader olaparib patent family maintained by AstraZeneca and its licensing partners.
The 24-day consolidation timeline suggests the court and parties recognised significant factual and legal overlap with earlier-filed actions (3:23-796 and 3:24-641) involving the same product and likely related patents or the same ANDA applicant. Consolidation under Fed. R. Civ. P. 42(a) is common in multi-ANDA pharmaceutical patent litigation to avoid duplicative proceedings and inconsistent rulings.
The plaintiffs are AstraZeneca AB, MSD International Business GmbH, Kudos Pharmaceuticals Limited, and AstraZeneca UK Limited. Kudos Pharmaceuticals is credited with originally discovering olaparib. The multi-entity plaintiff structure is consistent with co-ownership and licensing arrangements typical for major oncology assets developed through partnerships, and all co-owners or exclusive licensees are typically required to join as parties in US patent infringement suits.
Consolidation itself does not resolve infringement or validity issues — it means the olaparib patent dispute against Sandoz continues in a coordinated proceeding. In Hatch-Waxman cases, a timely-filed infringement suit typically triggers a 30-month stay of FDA ANDA approval. The consolidated trial schedule and any merits rulings on US11970530B2 and US11975001B2 will be the key determinants of when a generic olaparib product can lawfully enter the US market.
PatSnap Eureka searches patents and litigation data to answer instantly.